Aug 13, 2020
Armata Pharmaceuticals Announces Second Quarter 2020 Results and Provides General Corporate Update
Jun 17, 2020
Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections
May 14, 2020
Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update
Mar 30, 2020
Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.
Mar 19, 2020
Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update
Feb 13, 2020
Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.
Nov 12, 2019
Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update
Oct 31, 2019
Armata Pharmaceuticals Issues Letter to Shareholders
Oct 21, 2019
Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive
Oct 10, 2019
Armata Pharmaceuticals Expands Board of Directors with the Appointment of Research and Development Veteran Todd C. Peterson, Ph.D.
Sep 19, 2019
Armata Pharmaceuticals to Participate in the Ladenburg Thalmann 2019 Healthcare Conference
Sep 12, 2019
Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
Aug 14, 2019
Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
Aug 01, 2019
Armata Pharmaceuticals to Provide Corporate Update at the 39th Annual Canaccord Genuity Growth Conference
Jun 18, 2019
Armata Pharmaceuticals to Host Key Opinion Leader Meeting on Bacteriophage-Based Therapeutics on June 26 in New York
Jun 03, 2019
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with New Patent Allowances in Europe and Canada
May 28, 2019
Armata Pharmaceuticals Announces Publication of Successful Adjunctive Phage Treatment in Cystic Fibrosis Patient
May 09, 2019
C3J Therapeutics and AmpliPhi Biosciences Announce Successful Completion of Merger and Formation of Bacteriophage Company Armata Pharmaceuticals, Inc.